Interestingly, the involvement of CB2 has been demonstrated in tumor and stromal cells, as observed by the decrease of both cancer cell migration and CAFs α-SMA expression following the treatment with the selective antagonist JTE-907. The gene discussed is ACTA1; the disease is cancer.